Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
U-100 syringe marks: 25 IU (quarter), 50 IU (half), 75 IU (three-quarters), 100 IU (full), with tirzepatide mg equivalents at the two standard concentrations
Erratum in: J Cell Mol Med
In studies, it acts on GHRH receptors in the anterior pituitary, stimulating endogenous release of growth hormone (GH) and increasing IGF-1 systemically and also locally in various tissues, with effects investigated in metabolism and body composition
And generates a lot of toxic byproducts as well as different chronic intermittent stressors
It is FDA-approved for the treatment of type 2 diabetes and obesity
Use as prescribed by the physician
US$ 28.48
US$ 24.41
US$ 20.16
US$ 29.47
